If you are a member of the media and have questions about Bayer in Canada, please contact Marija Mandic, Director of Communications, at firstname.lastname@example.org, or 416-240-5376, or Emily Hanft, Senior Business Communications Partner, at email@example.com, or 416-240-5466.
November 27, 2013Bayer Is in Seventh Heaven!
November 14, 2013Real-World Data Confirm Clinical Value of Bayer’s Novel Oral Anticoagulant Xarelto in Protecting Patients Against Blood Clots
November 12, 2013Bayer receives approval for Eylea® as new drug to treat wet Age-Related Macular Degeneration Patients in Canada
October 21, 2013Bayer Comes Out on Top Once Again!
October 17, 2013Health Canada Approves A New Treatment Option For Patients With Gastrointestinal Stromal Tumours (GIST), A Rare Form Of Sarcoma
September 26, 2013Bayer Recognized as a Top Place to Work for Canada’s Young People for a Third Time
September 23, 2013Bayer receives approval for Adempas® as first drug to treat rare heart and lung disease
September 16, 2013150 Years of Bayer: pop song for a good cause
July 25, 2013New England Journal of Medicine Publishes Results of Two Pivotal Phase III Studies of Bayer’s Riociguat
July 18, 2013Bayer Announces that New England Journal of Medicine Publishes Results from Phase III ALSYMPCA Study of Radium 223 Dichloride
May 7, 2013Saluting Canadian innovators who embody Bayer’s philosophy: Science for a Better Life
May 6, 2013Many Canadian pet owners put animal’s health before their own
April 22, 2013Bayer Proves it is Easy Being Green
April 19, 2013Bayer’s Xarelto® (rivaroxaban tablet) Now Approved for the Treatment of Venous Thromboembolic Events and Prevention of Recurrent
April 2, 2013Bayer celebrates 150 years of Science for a Better Life
March 25, 2013First New Colon Cancer Treatment Since 2006 Received Priority Review From Health Canada And Is Now Approved For Canadian...
December 10, 2012Bayer Bee Care Center Helps Solve Bee Health’s Toughest Challenges
November 26, 2012Bayer Expands Leadership in Medical Information Technology through Acquisition of Toronto-based Radimetrics, Inc.
November 13, 2012New Canadian-Led Global Study of Xarelto® (rivaroxaban tablet) Initiated in Patients with Coronary or Peripheral Artery Disease
October 17, 2012Canadians in eight provinces now eligible for newly reimbursed treatment for stroke prevention in atrial fibrillation